Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316108 · ClinicalTrials.gov registry record · NA
Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 747
- Enrollment target
NCT00316108: Completed NA study, sponsored by Boston Scientific Corporation.
NCT00316108 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 747 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00316108, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 747 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be less than or equal to that of objective performance criteria (OPC) derived from historic controls undergoing surgical intervention with a carotid endarterectomy (CEA).
Interventions
- DEVICE WALLSTENT® Endoprosthesis™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-11 |
| Phase | NA |
What the finished NCT00316108 record still lists
NCT00316108 is an interventional study that assigns participants to a tested intervention. The registered 747 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which WALLSTENT® Endoprosthesis™ is the first listed.
NCT00316108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00316108 about?
NCT00316108 is a clinical study titled "Boston Scientific Embolic Protection, Inc. (EPI): A Carotid Stenting Trial for High-Risk Surgical Patients (BEACH)". The purpose of this study is to determine whether morbidity and mortality for high-risk surgical patients treated with the Carotid Wallstent in conjunction with the FilterWire EX and EZ System distal protection device will be less than or equal to that of objective performance criteria (OPC) derived...
What is the current status of trial NCT00316108?
This trial is currently completed. It is a NA study. The enrollment target is 747 participants. The study started on 2002-02. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00316108?
The interventions under investigation include: WALLSTENT® Endoprosthesis™ (DEVICE).
Who is sponsoring clinical trial NCT00316108?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00316108's enrollment target sits among peer trials
747 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia